KVP Capital Advisors, LP
KVP Capital Advisors, LP reported 36 holdings worth US$124M as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
KVP Capital Advisors, LP reported 36 holdings worth US$124M as of Sep 30, 2026. Largest: Praxis Precision Medicines, Inc., Whitehawk Therapeutics, Inc. and Silence Therapeutics PLC. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 36
- Value as reported
- US$124M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Praxis Precision Medicines, Inc. | 42,900 | US$12.5M | 10.1% |
| Whitehawk Therapeutics, Inc. | 2.17M | US$8.14M | 6.6% |
| Silence Therapeutics PLC | 684K | US$7.48M | 6.0% |
| Protagonist Therapeutics, Inc. | 53,000 | US$7.47M | 6.0% |
| MBX Biosciences, Inc. | 122K | US$7.12M | 5.7% |
| Erasca, Inc. | 455K | US$6.67M | 5.4% |
| Trevi Therapeutics, Inc. | 414K | US$5.93M | 4.8% |
| Tango Therapeutics, Inc. | 230K | US$5.75M | 4.6% |
| Edgewise Therapeutics, Inc. | 133K | US$5.4M | 4.3% |
| Tandem Diabetes Care, Inc. | 301K | US$4.91M | 3.9% |
| Achieve Life Sciences, Inc. | 462K | US$3.74M | 3.0% |
| Sutro Biopharma, Inc. | 227K | US$3.65M | 2.9% |
| Insmed Incorporated | 28,497 | US$3.25M | 2.6% |
| Savara, Inc. | 605K | US$3.12M | 2.5% |
| ArriVent BioPharma, Inc. | 102K | US$3.09M | 2.5% |
| IDEAYA Biosciences, Inc. | 79,700 | US$3.06M | 2.5% |
| Disc Medicine, Inc. | 43,750 | US$2.86M | 2.3% |
| United Therapeutics Corporation | 4,750 | US$2.57M | 2.1% |
| Viridian Therapeutics, Inc. | 125K | US$2.57M | 2.1% |
| Immix Biopharma, Inc. | 230K | US$2.4M | 1.9% |
| Design Therapeutics, Inc. | 185K | US$2.33M | 1.9% |
| Ocular Therapeutix, Inc. | 300K | US$2.3M | 1.9% |
| Travere Therapeutics, Inc. | 39,000 | US$2.3M | 1.8% |
| Mineralys Therapeutics, Inc. | 84,168 | US$2.12M | 1.7% |
| Vogenx Inc | 86,069 | US$1.96M | 1.6% |
| Nektar Therapeutics | 26,900 | US$1.63M | 1.3% |
| Bright Minds Biosciences Inc. | 31,813 | US$1.58M | 1.3% |
| Zura Bio Limited | 373K | US$1.55M | 1.2% |
| Artiva Biotherapeutics, Inc. | 200K | US$1.42M | 1.1% |
| Evolus, Inc. Common Stock | 150K | US$1.2M | 0.97% |
| Vera Therapeutics, Inc. | 32,700 | US$1.06M | 0.85% |
| Cabaletta Bio, Inc. | 505K | US$970K | 0.78% |
| Adial Pharmaceuticals, Inc | 210K | US$843K | 0.68% |
| Compass Therapeutics, Inc. | 771K | US$802K | 0.65% |
| Celcuity Inc. | 4,000 | US$318K | 0.26% |
| Axsome Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Scholar Rock Holding Corporation | 0 | US$0 | 0.00% |
| VYNE Therapeutics Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related